Novartis/Schering drug falls at clinical hurdle
The future for Novartis' experimental cancer drug looked grim after an ongoing clinical trial suggested that it was unlikely to boost survival rates of patients with colon cancer. This is the second setback for the drug this year, which Novartis is...